Featured Research

from universities, journals, and other organizations

Topiramate may have benefit as a weight-loss drug

Date:
June 6, 2011
Source:
The Endocrine Society
Summary:
The drug topiramate can help people lose weight as long as they can tolerate the side effects, according to authors of a new study that reviewed the medical literature, according to Brazilian researchers.

The drug topiramate can help people lose weight as long as they can tolerate the side effects, according to authors of a new study that reviewed the medical literature.

Brazilian researchers are presenting the results at The Endocrine Society's 93rd Annual Meeting in Boston.

Among more than 3,300 overweight or obese patients, those who took topiramate for at least four months lost 11.8 pounds more on average than individuals who took "dummy" pills, or placebo, found the meta-analysis, a systematic and quantitative review of published studies.

"Topiramate is not an approved drug for the treatment of obesity. Data from individual clinical trials might not be sufficient to support physicians' decision to prescribe it for this use, and robust evidence of its safety is lacking," said lead investigator Caroline Kramer, MD, PhD. She is an endocrinologist at Clinic Hospital of Porto Alegre in Brazil.

Currently topiramate is approved as an anti-convulsant for treatment of seizure disorders and for prevention in adults of migraine headaches.

The investigators pooled the research results of 10 randomized, controlled clinical trials (considered the gold standard in scientific research) that evaluated the benefits and adverse effects of topiramate prescribed for weight loss. They analyzed data about the effectiveness of topiramate on weight loss in 3,320 patients and data on adverse effects in 6,620 patients, she said.

According to the analysis, the duration and dosage of treatment affected the weight-loss benefits. Weight loss was higher when the drug was prescribed at doses of 96 to 200 milligrams per day for more than 28 weeks compared with less than 28 weeks, the authors reported. Compared with study subjects who took the placebo, topiramate-treated patients were seven times likelier to lose more than 10 percent of their body weight.

However, the authors found that patients were nearly two times more likely to stop topiramate treatment because of side effects than were those receiving placebo. The most common side effects, according to Kramer, included a burning sensation (paresthesia), typically around the mouth; impaired taste; and psychomotor disturbances, including slower thinking and reduced physical movements. Difficulty concentrating and memory impairment also were increased.

"Topiramate has a substantial effect on weight loss, at least comparable to the weight loss that other anti-obesity drugs induce," Kramer said. "We have so few pharmacological options for the treatment of obesity that I believe topiramate can be a useful tool together with diet and exercise."

She said it is important, however, for patients to understand the drug's known possible side effects and to be aware that it may have uncommon side effects that researchers have not yet observed.

The National Institutes of Health caution that people should use prescription weight-loss medications only if they are at increased risk of health problems because of their excess weight.


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Topiramate may have benefit as a weight-loss drug." ScienceDaily. ScienceDaily, 6 June 2011. <www.sciencedaily.com/releases/2011/06/110606092744.htm>.
The Endocrine Society. (2011, June 6). Topiramate may have benefit as a weight-loss drug. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2011/06/110606092744.htm
The Endocrine Society. "Topiramate may have benefit as a weight-loss drug." ScienceDaily. www.sciencedaily.com/releases/2011/06/110606092744.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins